President Donald Trump vowed to impose tariffs on pharmaceuticals within two weeks. Eli Lilly, a leader in the industry, could be harmed by the move, but it is already preparing for it.

Even though Eli Lilly and Company (NYSE:LLY) posted strong earnings, investors appeared to be underwhelmed. Our analysis says that investors should be optimistic, as the strong profit is built on ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.

INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) has announced a series of executive leadership transitions aimed at bolstering the company’s growth trajectory, particularly in the U.S. and ...

Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill ...

Claim your 7-day free trial now. Eli Lilly and Company LLY shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at ...

Eli Lilly announced a successful Phase 3 clinical trial of its new GLP-1 weight loss drug, orforglipron, which comes in pill form -- not an injection. This first trial showed weight loss of 7.9% ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

Patents, economies of scale, and a powerful distribution network support Eli Lilly’s wide moat. Lilly’s patent-protected drugs carry strong pricing power, which enables the firm to generate ...